A Case of Behçet’s Disease with Pericarditis, Thrombotic Thrombocytopenic Purpura, Deep Vein Thrombosis and Coronary Artery Pseudo Aneurysm

Chang Mo Kwon, M.D., Seung Hyun Lee, M.D., Jin Ho Kim, M.D., Kyu Hyung Lee, M.D., Hyun Do Kim, M.D., Yeong Hoon Hong, M.D. and Choong Ki Lee, M.D.

Division of Rheumatology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea

Behçet’s disease with concomitant thrombotic thrombocytopenic purpura (TTP), coronary artery stenosis and coronary artery pseudo aneurysm is rare. Here we report a case of Behçet’s disease with several cardiovascular complications, namely: pericarditis, deep vein thrombosis (DVT), TTP, coronary artery stenosis, and a coronary artery pseudo aneurysm.

A 37-year-old female presented with sudden dyspnea and syncope at our emergency room and underwent pericardiectomy and pericardial window formation for the diagnosis of cardiac tamponade with acute hemorrhagic pericarditis. Thereafter, TTP and DVT complicated her illness. After confirmation of Behçet’s disease on the basis of a history of recurrent oral and genital ulcers and erythema nodosum, remission was achieved after treatment with methylprednisolone pulse therapy, colchicine, catheter directed thrombolysis and thrombectomy. However, whilst maintaining anticoagulation therapy, a newly developed pericardial aneurysmal dilatation was noted on follow-up radiologic evaluation. Further evaluation revealed right coronary artery stenosis and a left coronary artery pseudo aneurysm; these additional problems were treated with the nonsurgical insertion of an endovascular graft stent. At the time of writing three months later after stent insertion, the aneurysm has continued to regress and no additional complications have intervened with combined immunosuppressive therapy.

Key Words : Behcet syndrome, Pericarditis, Hemorrhagic, Purpura, Thrombotic thrombocytopenic, Venous thrombosis, Aneurysm, False

INTRODUCTION

The main pathogenetic features of Behçet’s disease are vascular inflammation and thrombophilia. Clinical presentation is variable and may include: skin manifestations like recurrent oral or genital ulcers as well as, CNS, articular, and ocular signs as described by the international study group of Behçet’s disease as the key diagnostic features. Diverse vasculopathies and thrombophilia of any size and in any vessel, encompass vascular accidents of arterial, venous vasculitis, and thrombosis in Behçet’s disease. These findings however, rarely become complicated by vascular stenosis or aneurysmal dilatation. Here, we describe a case of Behçet’s disease that was complicated by cardiac tamponade with hemorrhagic pericarditis, TTP, DVT, coronary artery stenosis and a coronary artery pseudo aneurysm, the latter of which occurred during disease evolution.
Figure 1. Transthoracic echocardiography showing moderate pericardial effusion with fibrin debris and akinetic LV epicardium at the anterior, anterolateral wall and apex.

Figure 2. Peripheral blood smear showed microangiopathic hemolytic anemia with schistocytosis, anisocytosis, normoblast and thrombocytopenia.

CASE REPORT

A 37-year-old woman was transferred to our emergency room with the history of syncope. Three days previously, she experienced chest discomfort, dyspnea, palpitations and a low grade fever, but had no relevant past medical history or co-morbidity. At presentation her blood pressure was 80/50 mmHg, pulse rate 76/min, respiratory rate 36/min and body temperature 37.5°C. The physical examination was remarkable for: dyspnea, orthopnea, absence of normal heart sounds, and jugular vein dilatation: Additional tests revealed: low voltage ECG, sinus tachycardia and a large cardiac shadow on X-ray. Laboratory findings showed a pH of 7.37, PaCO₂ 18.8 mmHg, PaO₂ 88.5 mmHg, HCO₃⁻ 10.8 mmol/L on ABGA, hemoglobin 9.2 g/dL, white blood cell of 12900/μL, and platelet 476000/μL on CBC.ANA, rheumatoid factor, and VDRL were all negative and non-reactive. The patient had a suspected cardiac tamponade therefore a transthoracic echocardiography (TTE) was performed immediately and revealed moderate pericardial effusion and a hypokinetic LV at the anterior, anterolateral and apex portions of the heart (Figure 1). Pericardiectomy with a window formation was performed to remove the effusion and hematoma. The drained fluid had a white blood cell 225 (PML 100%), red blood cell 90,000/μL, LDH 1064U/L, and glucose 190 mg/dL; there were no organism on gram stain and culture. A class I cytology, indicating acute and chronic inflammation was revealed. On postoperative day 3, fever, dyspnea, oliguria and mental status changes developed and the patient deteriorated rapidly. A follow-up evaluation showed the serum hemoglobin to be 6.9 g/dL, white blood cell 14900/μL, platelets 18000/μL, and AST, ALT and CPK of 272, 151, and 247 U/L, respectively. Blood urea nitrogen was 40.6 mg/dL, creatinine 4.9 mg/dL, LDH 2279 U/L, PT 11.6 seconds and aPTT of 32 seconds.

A chest X-ray revealed a ground glass appearance in both lungs. The brain MRI was reported as normal. A peripheral blood smear was remarkable for schistocytosis, anisocytosis, normoblasts and a thrombocytopenia, suggestive of microangiopathic hemolytic anemia (Figure 2). All of these findings were compatible with the diagnosis of thrombotic thrombocytopenic purpura (TTP). Treatment with methylprednisolone pulse therapy was started (1 g/day for 3 days). Investigation for the etiology of TTP revealed that the patient had suffered from severe recurrent oral and genital ulcers. The ulcers were reported to be as frequent as 3 to 4 per month and were exacerbated by menstruation after the age of 20. The patient also reported taking medications intermittently for painful skin indurations and eruptions as well as arthralgia. Considering the clinical symptoms in total the diagnosis, of Behçet’s disease complicated by TTP and hemorrhagic pericarditis, was made. Treatment with methylprednisolone pulse therapy resulted in a dramatic response with improvements of the CBC, LFT, azotemia, and improved mental status. The patient went on to fully recover and returned to normal activities of daily living after complete recovery showed a normal right and left ventricular heart function and a minimal pericardial effusion. After discharge, the patient continued taking medication including colchicine 1.2 mg/day and prednisolone 5 mg/day. The patient continued to be followed.

Six months after discharge, the patient required readmission to the hospital. She presented with a sudden onset left leg swelling and pain that was diagnosed as a left proximal femoral vein thrombosis by duplex scan. There were no associated signs or symptoms such as dyspnea or fever. A venogram
demonstrated that a filling defect obstructed the left proximal femoral vein. The patient was treated with catheter directed thrombolysis using urokinase, thrombectomy and venoplasty and then started on combination anticoagulation therapy (Figure 3). Six months after maintenance therapy with coumadin, colchicines, and sulfasalazine was started, a homogenous soft tissue mass was found, incidentally, on routine laboratory and radiologic follow up. The soft tissue density was attached to the left perihilar area by the pulmonary conus (Figure 4). The laboratory tests showed a hemoglobin of 11.1 g/dL, platelet 324000/μL, WBC 6000/μL, ESR 39 mm/H, CRP 1.59 mg/dL, albumin 4.5 g/dL, LDH 503 U/L, BUN 11.8 mg/dL, creatinine 1.0 mg/dL, PT 29.7 second, INR 2.95.

Chest CT angiography and cardiac MRI revealed a 5x5cm sized round aneurysmal sac between the left atrium and left ventricle adjacent to the proximal pulmonary artery, but no definite stalk from the origin could be found (Figure 5). A doppler echocardiography demonstrated holosystolic ejection flow from the surface of the left ventricle (Figure 6). Despite the fact that the origin of aneurysmal stalk could not be identified, the pressure gradient calculated by the color doppler flow from the aneurysmal stalk to lumen was about 9 mmHg. The dilated vascular sac appeared to be a pseudo aneurysm with a coronary artery origin. A Tc-99m sestamibi scan was performed to investigate the possibility of myocardial ischemia. The scan revealed a reversible perfusion defect on the antero–septal wall (Figure 7). Subsequent coronary angiography allowed us to confirm the diagnosis of a pseudo aneurysm from the mid–left anterior descending artery (LAD), which interrupted distal flow by creating indentations and diffuse stenotic lesions along the whole length of the right coronary artery (RCA). In addition, a well developed collateral circulation was observed from the LAD and the left circumflex artery (LCX). An emergency operation was planned for aneurysmal resection and coronary artery
bypass grafting (CABG). However, because of the size and thus the risk of rupture, we opted instead for balloon angioplasty with a U-pass and graft stent. Implantation proceeded using a Graftmaster 3.0×19 mm at the mid LAD the origin of pseudo aneurysm (Figure 8). Because of the compromised distal flow of the RCA, the LAD would be of no advantage to the outcome of the CABG. If packed completely, it was expected that the aneurysmal sac would not grow any more and would regress by resorption and fibrosis. The administration of high dose glucocorticoid therapy (prednisolone 1 mg/kg/day) with azathio-
DISCUSSION

Behçet’s disease has a heterogenous presentation with variable symptoms including: mucocutaneous, ophthalmic, neurological, cardiovascular, pulmonary, gastrointestinal, urogenital and musculoskeletal involvement. The prevalence of vascular involvement in Behçet’s disease has been reported to range from 7.7 to 60.6%. Kabbaj et al reported 85% venous involvement, 10% arterial and 5% combined arterial and venous involvement2-4). Deep vein thrombosis, has been found to occur earlier in the course of disease than arterial disease, which develops after a median of 7 years. Deep vein thrombosis occurs primarily in the lower extremities, but involvement is possible at any site5).

Although the pathogenesis of thrombotic events in Behçet’s disease has not been elucidated, microscopic examinations of veins and arteries involved have demonstrated vasculitis. It has been postulated that a genetic predisposition to certain agents might result in damage and/or functional impairment of the vascular wall and endothelium of vessels. This observed damage may be due to impaired prostacyclin production, significantly higher levels of plasma endothelin-1,2, von
Figure 10. Six months later this chest X-ray revealed only a vestige of the aneurysm.

Willebrand factor, or anti-endothelial cell antibodies. The role of thrombophilia in Behçet’s disease with protein C or S, or antithrombin deficiency, in the presence of antiphospholipid antibodies or factor V Leiden have been investigated but results have been conflicting.

Cardiac involvement in Behçet’s disease is rare, but pericarditis, myocardial infarction, coronary arteritis, valvular regurgitation (especially aortic valve regurgitation), and an impaired conduction abnormalities have been reported. In our case, hemorrhagic pericarditis was identified as a presenting abnormality with no other identifiable sign or symptom.

Jabr et al. reported on the possibility of a link between Behçet’s disease and TTP and came to the conclusion that TTP had developed due to some other cause, e.g., the drugs administered or infection. Others reported hemolytic uremic syndrome (HUS) in patients with Behçet’s disease treated with cyclosporin. In our case, the patient had a history of prior surgery under general anesthesia, along with exposure to several medications (mainly antibiotics) before the onset of TTP. However, there were no definite signs of infection either physiologically or in culture. Nevertheless, she recovered completely and dramatically on high doses of glucocorticoid and conservative maintenance of antibiotics.

The prevalence of arterial occlusion in Behçet’s disease has been reported to range from 0.5 to 1.5% and can involve the coronary, subclavian, carotid, renal, pulmonary, or any peripheral artery and cause myocardial infarction, pulseless disease, stroke, hypertension, respiratory failure, or intermittent claudication. Aneurysm formation may coexist with arterial thrombosis. Common sites are the aorta and pulmonary, femoral, popliteal, subclavian and common carotid arteries, but any artery can be affected. It is significant that aneurysmal rupture is the leading cause of death in Behçet’s disease patients, and thus it should be deliberate to counter thrombophilia with anticoagulant therapy despite the presence of the thrombotic event.

The presence of an arterial pseudo aneurysm generally requires surgical repair with aneurysmectomy. Degeneration at the anastomotic site and thrombosis are not rare complications in the postoperative period. Ozeren et al. reported a pseudo aneurysm originating from the proximal left anterior descending artery and a true aneurysm of the right coronary artery with fistulization to the right atrium. They surgically corrected the pseudo aneurysm under cardiopulmonary bypass support by closing the neck of the false aneurysm using an endo-aneurysmal approach with a Gore-Tex patch. In our case, we adopted the approach of a stent graft implantation rather than surgical removal.

Several studies have been undertaken to examine graft stent implantation in Behçet’s disease. However, there is no prior report of the involvement of the coronary artery. The main advantages of endovascular treatment are lower mortality rates, e.g., 0.6% to 3.5%, even in high risk groups, and higher success rates (97%). Other advantages are shorter hospital stay and a shorter convalescence period before returning to normal life. In addition, the avoidance of general anesthesia and surgical dissection, this is especially important in Behçet’s disease because of its propensity for healing impairment.

Here, we report on a Behçet’s disease patient with rare complications related to the cardiovascular system during disease evolution. These problems included: hemorrhagic pericarditis, TTP, DVT, coronary artery stenosis, and a coronary artery pseudo aneurysm. The coronary pseudo aneurysm was treated with a combined approach of immunosuppression and endovascular non-surgical intervention.

Cardiovascular complications of Behçet’s disease must be treated with aggressive immunosuppression using a combination of corticosteroid and a cytotoxic agents. Anticoagulants and antiplatelet agents are judiciously required to address the risk of hemorrhage during the vasculitic process and that of aneurysmal rupture in cases of thrombotic complications. In patients with graft stent implantation, subsequent vascular thromboses are possible. For these cases some recommend anticoagulant therapy although this increases the risk of pseudo
aneurysm formation. As evidenced by the present case, anticoagulants like coumadin may cause aneurysm formation and growth in Behçet’s disease. Therefore, for patients with Behçet’s disease the early detection of cardiovascular complications is of cardinal importance as they are the leading cause of mortality. We recommend that physicians pay close attention to even minor complaints and that physical changes be scrutinized and that regular screening protocols are established for the early detection of cardiovascular complications in Behçet’s disease.

REFERENCES

1) International Study Group for Behçet’s disease. Criteria for diagnosis of Behçet’s disease. Lancet 335:1078-1080, 1990
2) Ko GY, Byun JY, Choi BG, Cho SH. The vascular manifestations of Behçet’s disease: angiographic and CT finding. Br J Radiol 73:1270-1274, 2000
3) Kabbaj N, Benjelloun G, Gueddari FZ, Dafiri R, Imani F. Vascular involvements in Behçet’s disease: based on 40 patient records. J Radiol 74:649-656, 1993
4) Yoo WH, Kim HK, Park JH, Park TS, Baek HS. Mediastinal mass and brachial plexopathy caused by subclavian arterial aneurysm in Behçet’s disease. Rheumatol Int 19:227-230, 2000
5) Calamia KT, Schirmer M, Mellikoglu M. Major vessel involvement of Behçet disease. Curr Opin Rheumatol 17:1-8, 2005
6) Espinosa G, Cervera R, Reverter JC, Tassies D, Font J, Ingelmo M. Vascular involvement in Behçet’s disease. Isr Med Assoc J 4:614-616, 2002
7) Espinosa G, Font J, Tassies D, Vidalier A, Duloufeu R, Lpes-Soto A, Cervera R, Ordinas A, Ingelmo M, Reverter JC. Vascular involvement in Behçet’s disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 112:37-43, 2002
8) Erol NK, Topsakal R, Abaci A, Ouzhan A. A case of atrioventricular complete block due to Behçet’s disease. Jpn Heart J 43:697-701, 2002
9) Jabri B, Shamseddine A, Utthman I, Chehal A, Taher A. Thrombotic thrombocytopenic purpura in a patient with Behçet’s disease. Arthritis Rheum 48:1468-1469, 2003
10) Beaullies H, de Groc F, Gubler MC, Wechsler B, le Hoang P, Baumeilow A, Chomette G, Jacobs C. Hemolytic uremic syndrome in patients with Behçet’s disease treated with cyclosporin A: report of 2 cases. Clin Nephrol 34:157-162, 1990
11) Doci D, Baldradi L, Capponcini C, Facchini F, Giudicissi A, Feletti C. Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura in a patient with Behçet’s disease treated with cyclosporin. Nephron 75:356–357, 1997
12) Silistrelli E, Karabay O, Erdal C, Serbest O, Gylene M, Catalzeck H, Ackel U. Behçet’s disease: treatment of polynuclear pseudoaneurysms pseudoaneurysm by an endovascular stent graft implantation. Ann Vasc Surg 18:118-120, 2004
13) Ozoren M, Dogan OV, Dogan S, Yucel E. True and pseudo aneurysms of coronary arteries in a patient with Behçet’s disease. Eur J Cardiothoracic Surg 25:465-467, 2004
14) Kutlu R, Gican O, Akbulut A, Turkoz B. Baysal T. Endovascular treatment of huge saccular abdominal aortic aneurysm in a young Behçet’s patient: mid-term result. BMC Med Imaging 2:1, 2002
15) Vasseur MA, Haulon S, Beregi JP, le Tourneau T, Prat A, Warembourgh H. Endovascular treatment of abdominal aneurysmal aortitis in Behçet’s disease. J Vasc Surg 27:974-976, 1998
16) Sakane T, Takeho M, Suzuki H, Iritaka G. Behçet’s disease. N Engl J Med 341:1284–1291, 1999